Figure S4 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis

Key Points

MAIN FINDING: The humanized CD36-blocking antibody effectively enhances antitumor immunity against liver cancer.
KEY EVIDENCE: The MYCOE/CTNNB1N90 mouse model demonstrated significant immune response upon treatment with CD36 antibody.
APPROACH: The study characterized liver cancer progression in a lipid-rich environment using a specific mouse model.
SIGNIFICANCE: This research highlights a potential new strategy to improve treatment outcomes for liver cancer patients.

Characterization shows CD36 antibody enhances antitumor immunity in liver cancer models, suggesting potential therapeutic applications.

Characterization of the progression and immune profile of the MYCOE /CTNNB1N90 liver cancer mouse model in the context of lipid-rich condition.

No takes yet. Share an insight, caveat, or question.

Tzeng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share